Business Wire
09 Nov 2025, 23:07 UTC · 46w ago
Verdict
Headline takes no side. We score VIR +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported positive Phase 2 trial results showing robust and sustained target not detected rates for its combination therapy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
5h ago
+104.9%
Price agrees with the score
$10.51 vs $5.13 close before publication (Nov 7) · not market-adjusted
VIR chart →
